• Home
  • NEW DAY MEDICINE
  • 5 (79) 2025
  • 17 -5 (79) 2025 - Nurbayev F.E., Raupov A.O. - COMORBIDITY OF ACID-RELATED GASTROINTESTINAL DISORDERS AND ISCHEMIC HEART DISEASE: MODERN PERSPECTIVES ON SHARED RISK FACTORS AND PATHOPHYSIOLOGICAL MECHANISMS

17 -5 (79) 2025 - Nurbayev F.E., Raupov A.O. - COMORBIDITY OF ACID-RELATED GASTROINTESTINAL DISORDERS AND ISCHEMIC HEART DISEASE: MODERN PERSPECTIVES ON SHARED RISK FACTORS AND PATHOPHYSIOLOGICAL MECHANISMS

COMORBIDITY OF ACID-RELATED GASTROINTESTINAL DISORDERS AND ISCHEMIC HEART DISEASE: MODERN PERSPECTIVES ON SHARED RISK FACTORS AND PATHOPHYSIOLOGICAL MECHANISMS

Nurbayev F.E. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Raupov A.O. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This review explores the comorbidity between acid-related gastrointestinal disorders and ischemic heart disease, focusing on shared risk factors and pathophysiological links. It highlights the role of systemic inflammation, metabolic imbalance, and pharmacological interactions in disease progression. The findings are based on meta-analyses and large-scale studies, offering insights for improved clinical management of comorbid conditions.

Keywords: comorbidity, gastroesophageal reflux disease, ischemic heart disease, anticoagulants, pathophysiological mechanisms

First page

87

Last page

90

For citation:Nurbayev F.E., Raupov A.O. - COMORBIDITY OF ACID-RELATED GASTROINTESTINAL DISORDERS AND ISCHEMIC HEART DISEASE: MODERN PERSPECTIVES ON SHARED RISK FACTORS AND PATHOPHYSIOLOGICAL MECHANISMS//New Day in Medicine 5(79)2025 87-90 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

  1. Ryabova A. Y., Shapovalova T. G., Shashina M. M., Guzenko T. N., Volkov S. V. [Clinical case of the sharp cholecystitis process under mask of a sharp myocardial infarction]. Eksp Klin Gastroenterol. 2015;(2):68–70. Russian. PMID: 25993877.
  2. Ivashkin V. T., Maev I. V., Trukhmanov A. S., et al. Reco mmen dations of the Russian Gastroenterological Association for the diagnosis and treatment of gastroesophageal reflux disease. Russian journal of gastroenterology, hepatology, coloproctology. 2020;30(4):70–97. (In Russ.) doi: 10.22416/1382–4376–2020–30–4–70–97.
  3. Shiraev TP, Bullen A. Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review. Heart Lung Circ. 2018 Apr;27(4):443–450. doi: 10.1016/j. hlc.2017.10.020.
  4. Nguyen T. N.M., Sha S., Chen L. J., Holleczek B., Brenner H., Schöttker B. Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: results from two large cohorts with new-user design. Aliment Pharmacol Ther. 2022 Jul;56(2):251–262. doi: 10.1111/apt.17050.
  5. Lavie C. J., Howden C. W., Scheiman J., Tursi J. Upper Gastrointestinal Toxicity Associated With Long- Term Aspirin Therapy: Consequences and Prevention. Curr Probl Cardiol. 2017 May;42(5):146–164. doi: 10.1016/j.cpcardiol.2017.01.006.
  6. Bjarnason I., Scarpignato C., Holmgren E., Olszewski M., Rainsford K. D., Lanas A. Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti- Inf lammatory Drugs. Gastroenterology. 2018 Feb;154(3):500–514. doi: 10.1053/j.gastro.2017.10.049.
  7. Kountouras J., Polyzos S. A., Katsinelos P., et al. Cardiocerebrovascular disease and Helicobacter pylori- related metabolic syndrome: We consider eradication therapy as a potential cardio- cerebrovascular prevention strategy. Int J Cardiol. 2017;229: 17–18. doi: 10.1016/j.ijcard.2016.11.265.
  8. Komarov A. L., Shahmatova O. O., Korobkova V. V., Kurilina E. V., Shuleshova A. G., Panchenko E. P. Gastric mucosa condition in patients with coronary artery disease and high risk of gastrointestinal bleeding (register REGATTA-1). Terapevticheskii Arkhiv. 2021;93(12):1457– 1462. (In Russ.) doi: 10.26442/00403660.2021.12.201224.
  9. Weissman S., Sinh P., Mehta T. I. et al. Atherosclerotic cardiovascular disease in inflammatory bowel disease: The role of chronic inflammation. World J Gastrointest Pathophysiol. 2020 Aug 12;11(5):104–113. doi: 10.4291/ wjgp.v11.i5.104
  10. Simanenkov V.I., Maev I. V., Tkacheva O. N. et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.) doi:10.15829/1728–8800–2021–2758.
  11. Jaaouani A., Ismaiel A., Popa S. L., Dumitrascu D. L. Acute Coronary Syndromes and Inflammatory Bowel Disease: The Gut- Heart Connection. J Clin Med. 2021 Oct 14;10(20):4710. doi: 10.3390/jcm10204710.
  12. Kristensen S.L., Ahlehoff O., Lindhardsen J. et al. Disease activity in infl ammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death – a Danish nationwide cohort study. PLoS One. 2013;8(2): e56944. doi: 10.1371/journal. pone.0056944.
  13. Mironova OIu, Isaikina MA, Khasieva SA. Аtherosclerosis and cardiovascular risk in patients with infl ammatory bowel disease. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(12):1533–1538. (in Russ.) doi: 10.26442/00403 660.2021.12.201225.
  14. Tena- Garitaonaindia M., Arredondo- Amador M., Mascaraque C., Asensio M., Marin J. J.G., MartínezAugustin O., Sánchez de Medina F. Modulation of intestinal barrier function by glucocorticoids: Lessons from preclinical models. Pharmacol Res. 2022 Mar;177:106056. doi: 10.1016/j.phrs.2022.106056.
  15. Andersen N.N., Rungoe C., Andersson M., Munkholm P., Pasternak B., Jess T. Tumor Necrosis Factor- Alpha Antagonists And Cardiovascular Disease In Infl ammatory Bowel Disease. European Crohn Colitis Organisation Congress, Vienna, Austria, February 14–16. 2013. Available at: https://www.ecco-ibd.eu/publications/ congress- abstract-s/abstracts-2013/item/19-tumornecrosis-factor- alpha-antagonists-and cardiovasculardisease-in-infl ammatory- bowel-disease.html. Access 05.05.05.2022.
  16. Glassner K.L., Abraham B. P., Quigley E. M.M. The microbiome and infl ammatory bowel disease. J Allergy Clin Immunol. 2020 Jan;145(1):16–27. doi: 10.1016/j. jaci.2019.11.003.
  17. Pepe M., Carulli E., Forleo C., Moscarelli M., Di Cillo O., Bortone A. S., Nestola P. L., Biondi- Zoccai G., Giordano A., Favale S. Inflammatory Bowel Disease and Acute Coronary Syndromes: From Pathogenesis to the Fine Line Between Bleeding and Ischemic Risk. Inflamm Bowel Dis. 2021 Apr 15;27(5):725–731. doi: 10.1093/ibd/ izaa160.
  18. Goldstone R.N., Steinhagen R. M. Abdominal Emer gencies in Inflammatory Bowel Disease. SurgClin North Am. 2019 Dec; 99(6):1141–1150. doi: 10.1016/j.suc.2019.08.007
  19. Ministry of Health of the Russian Federation. Clinical guidelines “Crohn’s disease” Age group: adults. 2020; (In Russ.) Available at: https://cr.minzdrav.gov.ru/schema/176_1. Access –5.05.2022.
  20. Bischoff S.C., Barbara G., Buurman W., Ockhuizen T., Schulzke J. D., Serino M., Tilg H., Watson A., Wells J. M. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterol. 2014 Nov 18;14:189. doi: 10.1186/s12876–014–0189–7.

    file

    download